標(biāo)題: Titlebook: Clinical Trials in Retinitis Pigmentosa Treatment; Jeffrey N. Weiss Book 2024 The Editor(s) (if applicable) and The Author(s), under exclu [打印本頁] 作者: Dangle 時(shí)間: 2025-3-21 18:44
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment影響因子(影響力)
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment影響因子(影響力)學(xué)科排名
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment網(wǎng)絡(luò)公開度
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment被引頻次
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment被引頻次學(xué)科排名
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment年度引用
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment年度引用學(xué)科排名
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment讀者反饋
書目名稱Clinical Trials in Retinitis Pigmentosa Treatment讀者反饋學(xué)科排名
作者: PAEAN 時(shí)間: 2025-3-21 23:12 作者: 吹牛需要藝術(shù) 時(shí)間: 2025-3-22 00:51
Introduction to the Case StudiesThis chapter contains a listing and summary of all the current active, recruiting studies for retinitis pigmentosa. Countries with current recruiting studies include the United States and Turkey, as well as the Latin American region.作者: overrule 時(shí)間: 2025-3-22 08:14
Koen H. Dam,Igor Nikolic,Zofia LukszoThis chapter contains a listing and summary of all the not yet recruiting stem cell studies for retinitis pigmentosa. Countries with not yet recruiting stem cell studies include Indonesia.作者: 后來 時(shí)間: 2025-3-22 10:16 作者: 聽寫 時(shí)間: 2025-3-22 14:40
https://doi.org/10.1007/978-3-030-75134-0This chapter contains a listing and summary of all the enrolling by invitation stem cell studies for retinitis pigmentosa treatment. Countries with enrolling by invitation stem cell studies include the United States and Indonesia.作者: 聽寫 時(shí)間: 2025-3-22 20:00
Agent-Based Modelling of Worker ExploitationThis chapter contains a listing and summary of all the completed gene therapy studies for retinitis pigmentosa treatment. Countries with completed gene therapy studies include the United States, India, and Saudi Arabia.作者: Certainty 時(shí)間: 2025-3-22 23:54
Mohamed Abdou,Lynne Hamill,Nigel GilbertThis chapter contains a listing and summary of all the current active, recruiting gene therapy studies for retinitis pigmentosa. Countries with current recruiting gene therapy studies include the United States and China.作者: Indigence 時(shí)間: 2025-3-23 03:31 作者: 產(chǎn)生 時(shí)間: 2025-3-23 07:17 作者: POINT 時(shí)間: 2025-3-23 11:42
Gian Paolo Jesi,Edoardo MollonaThis chapter contains a listing and summary of all the enrolling by invitation gene therapy studies for retinitis pigmentosa treatment. Countries with enrolling by invitation gene therapy studies include the United States, Canada, and India.作者: 珍奇 時(shí)間: 2025-3-23 16:58
https://doi.org/10.1007/978-3-319-18153-0This chapter contains a listing and summary of all the current active, not recruiting optogenetics studies for retinitis pigmentosa treatment. Countries with currently active optogenetics studies include the United States.作者: 豪華 時(shí)間: 2025-3-23 18:20
https://doi.org/10.1007/978-3-642-54432-3This chapter contains a listing and summary of all the completed studies for retinitis pigmentosa treatment. Countries with various other competed studies for retinitis pigmentosa treatment include the United States, China, Italy, and Turkey.作者: 技術(shù) 時(shí)間: 2025-3-24 01:53
Notes,This chapter contains notes from the author regarding Retinitis Pigmentosa and the relevant SCOTS I and II clinical trials.作者: municipality 時(shí)間: 2025-3-24 03:58 作者: 嘮叨 時(shí)間: 2025-3-24 08:46
Active, Recruiting Stem Cell StudiesThis chapter contains a listing and summary of all the current active, recruiting studies for retinitis pigmentosa. Countries with current recruiting studies include the United States and Turkey, as well as the Latin American region.作者: 無法解釋 時(shí)間: 2025-3-24 11:14
Not Yet Recruiting Stem Cell StudiesThis chapter contains a listing and summary of all the not yet recruiting stem cell studies for retinitis pigmentosa. Countries with not yet recruiting stem cell studies include Indonesia.作者: 現(xiàn)實(shí) 時(shí)間: 2025-3-24 14:59
Active, Not Recruiting Stem Cell StudiesThis chapter contains a listing and summary of all the current active, not recruiting stem cell studies for retinitis pigmentosa treatment. Countries with currently active studies include the United States and France.作者: 集合 時(shí)間: 2025-3-24 19:26
Enrolling by Invitation Stem Cell StudiesThis chapter contains a listing and summary of all the enrolling by invitation stem cell studies for retinitis pigmentosa treatment. Countries with enrolling by invitation stem cell studies include the United States and Indonesia.作者: 迅速成長(zhǎng) 時(shí)間: 2025-3-25 00:23 作者: BRAWL 時(shí)間: 2025-3-25 06:33 作者: 陳列 時(shí)間: 2025-3-25 10:43 作者: 清楚 時(shí)間: 2025-3-25 12:30 作者: CODE 時(shí)間: 2025-3-25 15:51 作者: 冷淡周邊 時(shí)間: 2025-3-25 20:49 作者: 手銬 時(shí)間: 2025-3-26 01:12
Completed StudiesThis chapter contains a listing and summary of all the completed studies for retinitis pigmentosa treatment. Countries with various other competed studies for retinitis pigmentosa treatment include the United States, China, Italy, and Turkey.作者: Fulsome 時(shí)間: 2025-3-26 05:05
https://doi.org/10.1007/978-3-031-58799-3Retinitis Pigmentosa; Treatment of Retinitis Pigmentosa; Clinical Trials in Retinitis Pigmentosa Treat作者: 牛的細(xì)微差別 時(shí)間: 2025-3-26 08:42
978-3-031-58801-3The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 現(xiàn)實(shí) 時(shí)間: 2025-3-26 14:03 作者: HATCH 時(shí)間: 2025-3-26 19:29 作者: adroit 時(shí)間: 2025-3-26 22:47 作者: fiscal 時(shí)間: 2025-3-27 01:31 作者: uveitis 時(shí)間: 2025-3-27 07:22
Introduction to Retinitis Pigmentosa, or a group of genetically determined degenerations characterized by rod dysfunction leading to cone loss. An estimated two million individuals worldwide are estimated to suffer from the disease. It is the leading cause of inherited blindness.作者: 不透氣 時(shí)間: 2025-3-27 13:16 作者: 射手座 時(shí)間: 2025-3-27 14:29
als in the treatment of‘Retinitis Pigmentosa.Covers active s.This book is a compendium of the worldwide ocular stem cell, gene therapy, optogenetic, and other miscellaneous studies treating Retinitis Pigmentosa registered with?Clinicaltrials.gov.?Clinicaltrials.gov?is the largest website listing of 作者: collagenase 時(shí)間: 2025-3-27 19:11 作者: GENRE 時(shí)間: 2025-3-28 01:44 作者: CHECK 時(shí)間: 2025-3-28 02:06 作者: 濕潤(rùn) 時(shí)間: 2025-3-28 10:19 作者: Gratulate 時(shí)間: 2025-3-28 14:20
Introduction to Retinitis Pigmentosa,57, though evidence for its existence presumably dates back earlier to 1744 when Ovelgun reported cases of familial night blindness. RP is a spectrum, or a group of genetically determined degenerations characterized by rod dysfunction leading to cone loss. An estimated two million individuals worldw作者: 偉大 時(shí)間: 2025-3-28 15:36
Treatments for Retinitis Pigmentosa,ht exposure might slow the progression of RP, but no effect was found. Likewise, there was no benefit of an increased intake of vitamin A, although vitamin E intake was found to be deleterious. At the present time, the only FDA approved treatment is Luxturna. (voretigene neparvovec) for a small sub-作者: misanthrope 時(shí)間: 2025-3-28 19:23
the studies. References are also included for the readers’ use. ?..Clinical Trials in Retinitis Pigmentosa Treatment.?is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers..978-3-031-58801-3978-3-031-58799-3作者: placebo-effect 時(shí)間: 2025-3-29 02:35 作者: Commodious 時(shí)間: 2025-3-29 05:37 作者: 季雨 時(shí)間: 2025-3-29 09:01 作者: opalescence 時(shí)間: 2025-3-29 14:54 作者: 皺痕 時(shí)間: 2025-3-29 15:57 作者: ADOPT 時(shí)間: 2025-3-29 21:26 作者: Toxoid-Vaccines 時(shí)間: 2025-3-30 00:33 作者: 剛毅 時(shí)間: 2025-3-30 06:29 作者: 牌帶來 時(shí)間: 2025-3-30 09:06 作者: 茁壯成長(zhǎng) 時(shí)間: 2025-3-30 15:29 作者: Fsh238 時(shí)間: 2025-3-30 20:14 作者: Osteoporosis 時(shí)間: 2025-3-31 00:20 作者: 威脅你 時(shí)間: 2025-3-31 03:19 作者: 背心 時(shí)間: 2025-3-31 07:30
https://doi.org/10.1007/978-1-4614-0248-0Der Wunsch, eine antibiotische Wirkung nachzuweisen, kann von zwei Richtungen ausgehen:作者: BILIO 時(shí)間: 2025-3-31 12:53 作者: BOAST 時(shí)間: 2025-3-31 15:07
